Riskpilot← Back to searchSign inGet full accessWaitless Diagnostics Sweden AB
ABActiveOrg 5568407018Vingårdsgatan 44 Lgh 1602Medical specialists activities · NACE 8622Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
+24% vs 2023
Equity ratio
99.8%
Financial strength
Net profit 2024
SEK 81K
+221% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -51K | +24% |
| Net profit | SEK 81K | +221% |
| Total assets | SEK 1,6M | -13% |
| Equity | SEK 1,6M | -13% |
| Employees | 0 | — |
Legal name
Waitless Diagnostics Sweden AB
Org number
5568407018
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
4 februari 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva diagnostisk konsultverksamhet samt forskning och utveckling inom hälso- och sjukvårdsområdet, samt äga och förvalta fast och lös egendom och därmed förenlig verksamhet.
Address
Vingårdsgatan 44 Lgh 1602
Email
magnus.backlund@diagnostisktcentrum.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | −122 | −10 | −67 | −51 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −10 | −122 | −10 | −67 | −51 |
| Net financials | 1 280 | 31 | 814 | 0 | 3 |
| Profit before tax | 1 270 | −1 | 804 | −67 | 81 |
| Tax | −0 | — | — | — | — |
| Net profit | 1 270 | −1 | 804 | −67 | 81 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 562 | 1 905 | 2 372 | 1 854 | 1 608 |
| Equity | 2 010 | 1 568 | 2 372 | 1 851 | 1 604 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 552 | 337 | 0 | 3 | 3 |
| Total debt | 552 | 337 | — | 3 | 3 |
EBITDA margin
-5146100.0%
This company
15.8%
Market median
-32570353% vs market
20202024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20202024
Return on equity
5.1%
This company
18.4%
Market median
-72% vs market
20202024
Net profit margin
8143000.0%
This company
8.1%
Market median
+100530764% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Waitless Diagnostics Sweden AB 
Drottningmottagningen Onkologi ABBoard members of Waitless Diagnostics Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Philip Jerlmyr | Chief Executive Officer | 0 companies |
| Lars Magnus Bäcklund | Board of Directors | 0 companies |